Imeik Technology Development Co

Imeik Technology Development Co Rule of 40

The Rule of 40 of Imeik Technology Development Co (300896.SZ) as of Nov 11, 2026 is 34.40 %. In the previous year, Rule of 40 was 81.15 % — a change of -57.62% (lower).

Rule of 40

34.40 %

YoY

-57.62%

Last updated:

Rule of 40 of Imeik Technology Development Co is 2025 34.40 % . Rule of 40 of Imeik Technology Development Co was 2024 81.15 % . It decreases by -57.62% lower compared to the previous year.

The Imeik Technology Development Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
88.91 CNY
Jan 1, 2019
136.53 CNY
Jan 1, 2020
98.06 CNY
Jan 1, 2021
181.94 CNY
Jan 1, 2022
110.67 CNY
Jan 1, 2023
123.21 CNY
Jan 1, 2024
81.15 CNY
Jan 1, 2025
34.40 CNY
The Imeik Technology Development Co Rule of 40 history
YEARRule of 40YoY
34.40 %-57.62%
81.15 %-34.14%
123.21 %+11.33%
110.67 %-39.17%
181.94 %+85.55%
98.06 %-28.18%
136.53 %+53.56%
88.91 %-11.27%
100.21 %+43.32%
69.92 %-4.42%
73.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Rule of 40 of Imeik Technology Development Co is 34.40 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co